Fujifilm Biotechnologies, the drug manufacturing arm of the Japanese conglomerate, is investing $3.2 billion in a new facility in Holly Springs, North Carolina, which is part of the state’s renowned Research Triangle, a biotech hub that is home to countless industry leaders.
Since its launch in the drug manufacturing space in 2011, when it was forced to pivot in the face of weakened demand for film thanks to the introduction of digital cameras, Fujifilm has continued to assert itself as a leader thanks to its engineering expertise, and its biotech arm is no different. It began with the purchase of two manufacturing facilities from Merck reportedly worth $490 million and now it has grown to 10 manufacturing sites across the U.S., the UK, Japan, and Denmark, including the new site in Holly Springs, its second in the region.
As a contract development and manufacturing organization (CDMO), Fujifilm Biotechnologies doesn’t work in drug development but supports drug companies in the manufacture of their own, including contracts with brands like Johnson & Johnson.
